(Q43640825)

25 November 2017

title

Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)--a novel potent and orally active immunosuppressive agent (English)

1 reference

25 November 2017

Bantia S

1

1 reference

25 November 2017

Miller PJ

2

1 reference

25 November 2017

Parker CD

3

1 reference

25 November 2017

Ananth SL

4

1 reference

25 November 2017

Horn LL

5

1 reference

25 November 2017

Kilpatrick JM

6

1 reference

25 November 2017

Morris PE

7

1 reference

25 November 2017

Hutchison TL

8

1 reference

25 November 2017

Montgomery JA

9

1 reference

25 November 2017

Sandhu JS

10

1 reference

25 November 2017

language of work or name

1 reference

1 June 2001

1 reference

International Immunopharmacology

25 November 2017

published in

1 reference

25 November 2017

volume

1

1 reference

25 November 2017

issue

6

1 reference

25 November 2017

page(s)

1199-1210

1 reference

Biochemistry of Diseases of Immunodevelopment

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900056-X

7 January 2021

Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900056-X

7 January 2021

Abnormal purine metabolism and purine overproduction in a patient deficient in purine nucleoside phosphorylase

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900056-X

7 January 2021

An abnormal form of purine nucleoside phosphorylase in a family with a child with severe defective T-cell-and normal B-cell immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900056-X

7 January 2021

Inhibition of purine nucleoside phosphorylase by 8-aminoguanosine: selective toxicity for T lymphoblasts

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900056-X

7 January 2021

Preliminary report on 8-amino-9-(2-thienylmethyl)guanine (PD 119,229), a novel and potent purine nucleoside phosphorylase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900056-X

7 January 2021

Comparative in vitro and in vivo activities of two 9-deazaguanine analog inhibitors of purine nucleoside phosphorylase, CI-972 and PD 141955

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900056-X

7 January 2021

In vivo and in vitro pharmacologic activity of the purine nucleoside phosphorylase inhibitor BCX-34: the role of GTP and dGTP

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900056-X

7 January 2021

Allosteric regulation of calf thymus ribonucleoside diphosphate reductase

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900056-X

7 January 2021

PD 141955 and CI-972: 9-deazaguanine analog purine nucleoside phosphorylase inhibitors. I. Suppression of the human mixed lymphocyte reaction (MLR).

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900056-X

7 January 2021

Effects of a novel purine nucleoside phosphorylase inhibitor, BCX-34, on activation and proliferation of normal human lymphoid cells

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900056-X

7 January 2021

Pharmacokinetics and pharmacodynamics of peldesine (BCX-34), a purine nucleoside phosphorylase inhibitor, following single and multiple oral doses in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900056-X

7 January 2021

One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900056-X

7 January 2021

A methodological study of E-rosette formation using AET-treated sheep red blood cells

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900056-X

7 January 2021

Enzymatic assay for deoxyribonucleoside triphosphates using synthetic oligonucleotides as template primers

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900056-X

7 January 2021

Pharmacologic manipulation of graft versus host induced splenomegaly

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900056-X

7 January 2021

Transfer of a functional human immune system to mice with severe combined immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900056-X

7 January 2021

PD 141955 and CI-972: 9-deazaguanine analog purine nucleoside phosphorylase inhibitors. II. Effects on nucleoside catabolism in human and rat blood in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900056-X

7 January 2021

Inhibitors of the enzyme purine nucleoside phosphorylase as potential therapy for psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900056-X

7 January 2021

Central nervous system dysfunction and erythrocyte guanosine triphosphate depletion in purine nucleoside phosphorylase deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900056-X

7 January 2021

Mitochondrial basis for immune deficiency. Evidence from purine nucleoside phosphorylase-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900056-X

7 January 2021

Different pathways for deoxyguanosine toxicity in T-lymphocytes of various developmental stages

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900056-X

7 January 2021

The use of SCID mice in biotechnology and as a model for human disease

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900056-X

7 January 2021

10.1016/S1567-5769(01)00056-X

Identifiers

DOI

1 reference

25 November 2017

1 reference